MS: Busting the Myths
February 29, 2024 | Treatments
In December 2023, Pharmac proposed to decline funding for inactive applications, this included an application to fund Sativex for MS spasticity. MSNZ has written to the Pharmac Board to ask that this application remain live and we be permitted to present more evidence regarding the patient’s need. Sativex is currently unfunded and costs approximately $300 per month.
Should our request be accepted, MSNZ will be looking for stories from people with MS to highlight the burden that non-funded Sativex places on those diagnosed and their whānau. You are welcome to send your personal story to info@msnz.org.nz.
View our submission here.